Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Metastatic Breast Cancer
Phase PHASE3
Enrollment 376
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: SKB264 — IV infusion on day 1 and Day 15 of each 28 day cycle
  • Drug: Eribulin — 1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
  • Drug: Capecitabine — 1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle
  • Drug: Gemcitabine — 1000 mg/m2, IV infusion on day 1 and Day 8 of each 21day cycle
  • Drug: Vinorelbine — 25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle

Primary Outcomes

  • Progression-free survival (PFS) assessed by BIRC per RECIST 1.1. (up to 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-10-31
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 376 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Contact Information
Study Contact:
Yina Diao
86-13402828610
diaoyina@kelun.com
BingHe Xu, PhD
Cancer Hospital Chinese Academy of Medical Science
Interventions
  • Drug: SKB264 — IV infusion on day 1 and Day 15 of each 28 day cycle
  • Drug: Eribulin — 1.4 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
  • Drug: Capecitabine — 1000-1250 mg/m2, po, bid, from day 1 to Day 15 of each 21 day cycle
  • Drug: Gemcitabine — 1000 mg/m2, IV infusion on day 1 and Day 8 of each 21day cycle
  • Drug: Vinorelbine — 25 mg/m2, IV infusion on day 1 and Day 8 of each 21 day cycle
Study Locations (1 sites)
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria: * Males or females aged ≥ 18 to ≤ 75 years at the time of signing the ICF; * Histologically and/or cytologically confirmed HR+/HER2- breast cancer based on pathology reports on recent biopsy specimens or other pathological samples; * Patients who had failed at least one line of systemic chemotherapy in unresectable locally advanced, recurrent, or metastatic stage; * Patients with at least one measurable lesion per RECIST 1.1 criteria; those with only skin or bone lesions cannot be included; * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1; * Expected survival ≥ 12 weeks; * Adequate organ and bone marrow function; * Patients who are eligible for a chemotherapy regimen in the control group; * Female patients of childbearing potential and male patients with partners of childbearing potential who use effective medical contraception from the time of signing the informed consent form until 6 months after the last dose; * Patients who voluntarily participate in the study and sign the ICF, and able to comply with the visit and related procedures stipulated in the plan. Exclusion Criteria: * Patients with a history of central nervous system (CNS) metastases or current CNS metastases; * Patients with other malignancies (except cured basal or squamous cell skin cancer or carcinoma in situ of the cervix) within 3 years prior to the first dose; * Patients with any cardio cerebral Vascular disease or cardio cerebral vascular risk factors may affect investigational treatment; * Uncontrollable systemic diseases assessed by the investigator; * History of (noninfectious) interstitial lung disease (ILD)/noninfectious neumonitis requiring steroid therapy and current ILD/noninfectious pneumonitis, or ILD/noninfectious pneumonitis at screening that cannot be excluded by imaging; * Clinically serious lung injuries caused by lung diseases; * Patients with active chronic Inflammatory bowel disease, gastrointestinal obstruction, severe ulcer, gastrointestinal perforation, abdominal abscess or acute gastrointestinal bleeding; * Toxicities from prior anti-tumor therapy not recovering to ≤ Grade 1; * Active hepatitis B or hepatitis C; * Human immunodeficiency virus (HIV) antibody test positive or a history of acquired immunodeficiency syndrome (AIDS), known active syphilis infection; * Known allergy or hypersensitivity to SKB264, or the excipients of SKB264; * Prior TROP2 targeted therapy, prior topoisomerase I inhibitor therapy, including antibody-drugconjugate(ADC) therapy; * Patients who received major surgeries 4 weeks prior to the first dose of study treatment or planned to receive major surgeries during the study ; * Patients with concomitant infections requiring systemic antibiotic therapy within 2 week prior to the first dose of study treatment; * Patients who have received live vaccines within 30 days prior to the first dose, or are scheduled to receive live vaccines during the study; * Pregnant or lactating women.
Conditions Emotions, Anhedonia, Depression
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to use smartphone technology to capture individual location emotional and cognitive data, to examine how real-world behaviors thoughts, emotions, and brain activity are related to one another.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: Modifying Exploration — Participants in this group will use a mobile phone sensor data application that uses an accelerometer, Wireless Fidelity (WiFi) and/or GPS designed for smartphone devices. This technology allows the phones to capture information automatically and passively on the participant's activity. The application will be collecting participants' data 24 hours a day, 7 days a week. Participants will be asked to make alterations to their exploration levels approximately 20 days of their participation in the study.

Primary Outcomes

  • Change in positive emotional response as measured by ecological momentary assessment (Baseline, up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-02
Completion: 2028-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Miami
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Aaron S Heller, PhD (PRINCIPAL_INVESTIGATOR) - University of Miami
Contact Information
Study Contact:
Isabella C D'Ottone, BA
3052849555
icd30@miami.edu
Isabella C D'Ottone, BA
3052849555
icd30@miami.edu
University of Miami
Aaron S Heller, PhD
University of Miami
Interventions
  • Behavioral: Modifying Exploration — Participants in this group will use a mobile phone sensor data application that uses an accelerometer, Wireless Fidelity (WiFi) and/or GPS designed for smartphone devices. This technology allows the phones to capture information automatically and passively on the participant's activity. The application will be collecting participants' data 24 hours a day, 7 days a week. Participants will be asked to make alterations to their exploration levels approximately 20 days of their participation in the study.
Study Locations (1 sites)
University of Miami, Coral Gables, Florida 33146 United States
Eligibility Criteria
Inclusion Criteria: * Must agree to give informed consent * Must be willing to have an functional Magnetic Resonance Imaging (FMRI) scan * Must be able to receive and respond to daily text messages assessing current emotion * Must be willing to download and run a GPS tracking application (FollowMee) onto their smartphone for a four-month period Exclusion Criteria: * history of head trauma, seizures, or neurological disorders * severe/unstable medical conditions * conditions that interfere with MRI * pregnancy * lifetime psychotic/bipolar disorder * chronic/severe substance or alcohol abuse/dependence * antipsychotic medication
Conditions Triple Negative Breast Cancer
Phase PHASE3
Enrollment 348
Locations 43 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

TNBC is known for poor prognosis, aggressive patterns of disease, and significant molecular heterogeneity. (Neo)adjuvant chemotherapy (NACT) is standard of care in all node-positive and in node-negative patients with a tumour size \>5 mm according to current National Comprehensive Cancer Network (NCCN) guidelines. However, TNBC patients with lower stage disease do clearly have a better prognosis compared to more advanced stages. Patients with stage I-II node-negative disease have 3-5 year iDFS rates of 80-90% (with majority of relapses within the first three years) as shown in several trials.Although survival results appear much better in the lower vs. higher stages, there is a high clinical need in this most common group of TNBC patients in Western Europe and USA.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Sacituzumab govitecan — 10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle
  • Drug: Pembrolizumab — 200 mg every 3 weeks (q3w)

Primary Outcomes

  • pathological complete remission (pCR) (at surgery)
  • invasive disease-free survival rate (iDFS), (after 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-10-10
Completion: 2029-09
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 348 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Women's Cancer Study Group GmbH
Collaborators: Merck Sharp & Dohme LLC, Gilead Sciences
Principal Investigators:
  • Peter Schmid, Prof Dr PHD (PRINCIPAL_INVESTIGATOR) - Westdeutsche Studiengruppe GmbH
  • Nadia Harbeck, Prof Dr (PRINCIPAL_INVESTIGATOR) - Breast Centre, Dept. Obstetrics & Gynaecology and CCC Munich LMU University Hospital
  • Oleg Gluz, PD Dr (PRINCIPAL_INVESTIGATOR) - Breast Centre, Evang. Bethesda-Hospital, Moenchengladbach
Contact Information
Study Contact:
Oleg Gluz, PD Dr.
+492161566230
oleg.gluz@wsg-online.com
Anja Braschoß
+4917682119153
anja.braschoss@wsg-online.com
Martina Koch
Stadtklinik Baden-Baden / Brustzentrum
Interventions
  • Drug: Sacituzumab govitecan — 10 mg/kg twice on Days 1 and 8 of a continuous 21-day treatment cycle
  • Drug: Pembrolizumab — 200 mg every 3 weeks (q3w)
Study Locations (43 sites)
Stadtklinik Baden-Baden / Brustzentrum, Baden-Baden, Baden-Wurttemberg 76532 Germany
Kliniken Böblingen, Böblingen, Baden-Wurttemberg 71032 Germany
Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg im Breisgau, Baden-Wurttemberg 79110 Germany
SLK Kliniken Heilbronn, Frauenklinik, Heilbronn, Baden-Wurttemberg 74078 Germany
Universitätsklinikum Tübingen, Tübingen, Baden-Wurttemberg 72076 Germany
Universitätsklinikum Ulm, Ulm, Baden-Wurttemberg 89075 Germany
GRN Klinik Weinheim, Weinheim, Baden-Württembergs 69469 Germany
Hämatologie-Onkologie im Zentrum MVZ GmbH, Augsburg, Bavaria 86150 Germany
Universitätsklinikum Augsburg A.ö.R., Augsburg, Bavaria 86156 Germany
Rotkreuzklinikum München, München, Bavaria 80637 Germany
Eligibility Criteria
Inclusion Criteria: 1. ER + PR negative or low positive (≤10% positive cells in IHC), and HER2 negative (i.e., IHC 0 - 1+ or IHC 2+ with FISH negative) breast cancer 2. All patients, independent from gender 3. ≥18 years at diagnosis 4. Histologically confirmed unilateral, primary invasive carcinoma of the breast Note: bilateral, multicentric, or multifocal carcinoma may be included, if there is a clear target lesion, that is subject to treatment decisions and solely evaluated and documented for study purposes. 5. Clinical stage I: cT1a-c, cN0 (clinical stage II only, if patient does not qualify for neoadjuvant polychemotherapy+PEM, e.g., elderly population, per investigator´s decision) 6. No clinical evidence for distant metastasis (M0) 7. Tumour block available for central pathology review 8. Performance Status ECOG ≤ 1 or KI ≥ 80% 9. Negative pregnancy test (urine or serum) within 7 days prior to registration in premenopausal patients 10. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements 11. The patient must be willing and able to comply with the requirements and restrictions in this protocol and accessible for treatment and follow-up 12. Laboratory requirements: * Leucocytes ≥3.5 109/L, * Neutrophils \> 1.5 109/L, * Platelets ≥100 109/L, * Haemoglobin ≥10 g/dL, * AP \< 5.0 ULN, * AST ≤2.5 x ULN, * ALT ≤2.5 x ULN, * Total bilirubin ≤1 x ULN, * Creatinine ≤1.5 × ULN OR clearance ≥30 mL/min for participant with creatinine levels \>1.5 × institutional ULN 13. Clinical assessments: • LVEF within normal limits of each institution, measured by echocardiography and normal ECG (within 42 days prior to treatment) 14. The following age-specific requirements apply: * Women aged \<50 years will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the site. * Women aged ≥ 50 years will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments. 15. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of child-bearing potential if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to randomization/study enrolment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method. 16. Female patients of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception, presented in Table 1 (see Section 4.4.2), from the time of screening and must agree to continue using such precautions for 7 months after the last dose of IMP. Not all methods of contraception are highly effective. Female patients must refrain from breastfeeding while on study and for 7 months after the last dose of IMP. Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic, or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable. 17. Female patients must not donate, or retrieve for their own use, ova from the time of randomisation and throughout the study treatment period, and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to enrolment in this study. 18. A male participant must agree to use a contraception as detailed in Appendix C of this protocol during the treatment period and for at least 7 months after the last dose of study treatment and refrain from donating sperm during this period. Exclusion Criteria: 1. Known hypersensitivity reaction to the compounds or incorporated substances of the IMPs 2. Prior malignancy with a disease-free survival of \< 5 years, except curatively treated basalioma of the skin or pTis of the cervix uteri 3. Any history of invasive breast cancer 4. Previous or concurrent treatment with cytotoxic agents for any non-oncological reason unless clarified with sponsor 5. Concurrent treatment with other experimental drugs 6. Participation in another interventional clinical trial with or without any investigational not marketed drug within 30 days prior to study entry 7. Concurrent pregnancy; patients of childbearing potential or potentially childbearing partners of male patients must implement a highly effective (less than 1% failure rate) non-hormonal contraceptive measures during the study treatment 8. Breast feeding woman 9. Reasons indicating risk of poor compliance 10. Patients not able to consent 11. Known polyneuropathy ≥ grade 2 12. Severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study including recovery from major surgery, autoimmune disease, known psychiatric/substance abuse disorders, acute cystitis, ischuria, and chronic kidney disease 13. Uncontrolled infection requiring i.v. antibiotics, antivirals, or antifungals 14. History of pneumonitis 15. Active primary immunodeficiency, known human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Patients should be tested for HIV prior to randomisation if required by local regulations or ethics committee (EC). 16. Have active hepatitis B virus (HBV) or hepatitis C virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded. * Patients who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease. * Patients who test positive for HCV antibody will require HCV RNA by quantitative PCR for confirmation of active disease. Patients with a known history of HCV or a positive HCV antibody test will not require a HCV antibody at screening and will only require HCV RNA by quantitative PCR for confirmation of active disease. 17. Patients who test positive for HIV antibody.
Conditions Type 2 Diabetes, Ketone Body Metabolism,...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is being done to evaluate how a ketone ester (KE) supplement affects heart function and health in people with diabetes compared to a placebo supplement (made with standard food ingredients that do not contain ketone esters).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Dietary Supplement: Ketone Ester Acute — Participants will undertake a controlled feeding intervention where they will consume 25g of C8 Ketone Diester with a meal, and images obtained before and after consumption. The supplement powder contains 12.5 g C8 Diester, sodium caseinate and soluble corn fiber, per serving. The powder contains 120 kcal, 0 g fat, 3 g carbohydrate, and 0 g protein. A standardized meal will be provided to subjects to consume with their allocated supplement during the MRI visits. This meal is formulated with whole foods (i.e. chicken, rice, and a fruit bar) as a mix of macronutrients (29% protein, 3% fat, and 68% carbohydrate - not including the supplements). The meal consists of \~700kcal of food and will be standardized between all visits and subjects.
  • Dietary Supplement: Placebo Acute — Participants will undertake a controlled feeding intervention where they will drink two servings of the placebo with a meal, and images obtained before and after consumption. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any BHB, which will be replaced with a similar caloric content of fat in the form of canola oil.

Primary Outcomes

  • Change in Cardiac MRI measures of cardiac function (Baseline, 2 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-06
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University
Principal Investigators:
  • Yuchi Han, MD, MMSc (PRINCIPAL_INVESTIGATOR) - Ohio State University
Contact Information
Study Contact:
Debbie Scandling, BS
614-688-5623
debbie.scandling@osumc.edu
Christopher Crabtree, MS
crabtree.223@osu.edu
Debbie Scandling
614-688-5623
debbie.scandling@osumc.edu
The Ross Heart Hospital
Interventions
  • Dietary Supplement: Ketone Ester Acute — Participants will undertake a controlled feeding intervention where they will consume 25g of C8 Ketone Diester with a meal, and images obtained before and after consumption. The supplement powder contains 12.5 g C8 Diester, sodium caseinate and soluble corn fiber, per serving. The powder contains 120 kcal, 0 g fat, 3 g carbohydrate, and 0 g protein. A standardized meal will be provided to subjects to consume with their allocated supplement during the MRI visits. This meal is formulated with whole foods (i.e. chicken, rice, and a fruit bar) as a mix of macronutrients (29% protein, 3% fat, and 68% carbohydrate - not including the supplements). The meal consists of \~700kcal of food and will be standardized between all visits and subjects.
  • Dietary Supplement: Placebo Acute — Participants will undertake a controlled feeding intervention where they will drink two servings of the placebo with a meal, and images obtained before and after consumption. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any BHB, which will be replaced with a similar caloric content of fat in the form of canola oil.
Study Locations (1 sites)
The Ross Heart Hospital, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years old and ≤ 80 years old 2. Type II Diabetes Mellitus 3. Stable medical therapy for at least 1 months as determined by the treating physician (no plan to change between the two testing sessions) 4. Dose of oral diuretics changes allowed, but must be stable for 1 week prior to randomization 5. Body Mass Index (BMI) ≥ 25 6. Ability to participate in exercise treadmill testing (only if CPET is performed) 7. Ability to sign written consent Exclusion Criteria: 1. Women who are pregnant, current breast-feeding, or have intention to become pregnant while in the trial 2. Known allergy or sensitivity to Gadolinium based contrast agents 3. Implanted pacemaker, cardioverter defibrillator, cardiac resynchronization therapy, left ventricular assist device 4. Other metallic implants/aneurysm clips that are contraindicated in MRI 5. Claustrophobia 6. History of severe kidney disease with eGFR\<30 ml/kg/1.73m2 7. Type I diabetes 8. History of diabetic ketoacidosis 9. Prior diagnosis of oxygen dependent pulmonary disease 10. Body Mass Index (BMI) \< 25 11. Major surgery (major according to the investigator's assessment) performed within 90 days prior to screening, or major scheduled elective surgery (e.g. hip replacement) within 90 days after screening 12. Acute or chronic liver disease, defined by serum levels of transaminases or alkaline phosphatase more than three times the upper limit of normal at screening 13. Gastrointestinal surgery or gastrointestinal disorder that might interfere with supplement consumption. Prior bariatric surgery allowed if weight-stable for past 3 months. 14. Any documented active or suspected malignancy or history of malignancy within 2 years prior to screening, except appropriately treated basal cell carcinoma of the skin, in situ carcinoma of the uterine cervix, or low-risk prostate cancer (subjects with pre-treatment prostate-specific antigen levels of \<10 ng/mL, and biopsy Gleason scores of ≤6 and clinical stage T1c or T2a) 15. Presence of any disease other than diabetes that results in a life expectancy of \<1 year (in the opinion of the investigator) 16. Current enrolment in another investigational device or drug study or completion within \<30 days of a trial of another investigational device or drug study. 17. Chronic alcohol or drug abuse or any condition that, in the investigator's opinion, will make the subject unlikely to fulfil the trial requirements or complete the trial 18. Any other clinical condition that might jeopardize subject safety during participation in this trial or prevent the subject from adhering to the trial Protocol. 19. Unable or unwilling to follow guidelines of assigned supplement group. 20. Allergy to test article ingredients, or lactose intolerance 21. The subject cannot currently be on a low-carb diet plan. 30-day washout would be required. 22. Refusal to consent
Conditions Breast Cancer, Axillary Nodal Disease, F...
Phase PHASE2
Enrollment 45
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to determine the recurrence rates and survival of patients with clinical T1-2N0 ER+/Her2- invasive breast cancer who have biopsy proven image detected nodal disease treated with upfront lumpectomy or mastectomy with TAD followed by adjuvant therapy. This is a prospective, single arm phase II clinical trial. Patients will be screened and enrolled per eligibility criteria. Patient, tumor, and treatment data will be documented.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Breast Surgery (BCS or mastectomy) with TAD/SNB — Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
  • Radiation: Adjuvant Radiation Therapy — Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy

Primary Outcomes

  • Regional recurrence rate (5 Years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-04-07
Completion: 2031-04
Eligibility
Age: 45 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Alice Chung
Principal Investigators:
  • Alice Chung, MD (PRINCIPAL_INVESTIGATOR) - Cedars-Sinai Medical Center
Contact Information
Study Contact:
Clinical Trial Navigator
310-423-5842
GroupCancerTrialInformation@cshs.org
Clinical Trial Recruitment Navigator
310-423-5842
GroupCancerTrialInformation@cshs.org
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Scott Karlan, MD
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Interventions
  • Procedure: Breast Surgery (BCS or mastectomy) with TAD/SNB — Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
  • Radiation: Adjuvant Radiation Therapy — Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
Study Locations (3 sites)
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California 90048 United States
CS Cancer at Huntington Cancer Center, Pasadena, California 91105 United States
CS Cancer at Valley Oncology Medical Group, Tarzana, California 91356 United States
Eligibility Criteria
Inclusion Criteria: * Women age ≥ 45 * Clinical T1-2N0 ER+ invasive breast cancer * US detected biopsy proven axillary nodal disease * Written informed consent obtained from subject and ability for subject to comply with the requirements of the study. Exclusion Criteria: * Palpable nodes on physical exam * Her2+ or ER- invasive breast cancer * Extranodal extension \> 3 mm on nodal biopsy * More than 2 suspicious nodes on preoperative imaging
Conditions Breast Cancer
Phase PHASE2
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Evaluate the efficacy and safety of Disitamb Vedotin combined with pyrotinib in HER2 positive early breast cancer

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Disitamb Vedotin ,pyrotinib — Disitamb Vedotin combined with pyrotinib

Primary Outcomes

  • pathologic complete response(pCR) (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-11-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Collaborators: First Affiliated Hospital of Wenzhou Medical University
Contact Information
Study Contact:
Wei Li, Ph.D
025-68307102
real.lw@163.com
Wei Li, Ph.D
025-68307102
real.lw@163.com
Jiangsu Provincial People's Hospital
Interventions
  • Drug: Disitamb Vedotin ,pyrotinib — Disitamb Vedotin combined with pyrotinib
Study Locations (1 sites)
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu 210000 China
Eligibility Criteria
Inclusion Criteria: 1.18 to 75 years old (at the time of signing the informed consent form), regardless of gender. 2\. Subject type and disease characteristics. Histologically confirmed HER2 positive EBC subjects: 1. evaluated as HER2 positive in local laboratories according to ASCOCAP guidelines. 2. Single and multifocal tumors (greater than 1 tumor area limited to the same quadrant as the primary tumor) must be sampled from 1 lesion and laboratory confirmed as HER2 positive. 3. Multicenter tumors (multiple tumors involving more than one breast quadrant) must sample one lesion from each affected quadrant and be confirmed as HER2 positive by the central laboratory. 4. According to ASCOCAP guidelines, tumors are either HR positive or HR negative (ER and PgR negative). 5. Clinical staging at visit (based on breast X-ray or breast MRI evaluation): Stage II-IIIC determined by the AJCC staging system, 8th edition. (f) Lymph node involvement is determined by fine needle aspiration or coarse needle aspiration biopsy (if applicable). 3\. When randomized, ECOG physical fitness status is 0 or 1 point. Exclusion Criteria: 1. Previous history of invasive breast cancer. 2. Stage IV breast cancer according to AJCC staging system version 8. 3. Within 3 years, there is any primary malignant tumor, except for fully resected non-melanoma skin cancer or cured in situ disease. 4. DCIS medical history, except for the subjects who only received Mastectomy 5. According to the judgment of the researchers, there is evidence of any diseases (such as severe or uncontrolled systemic diseases, including persistent or active infections, uncontrolled hypertension, kidney transplantation and active bleeding diseases, and severe chronic gastrointestinal diseases related to diarrhea) that the researchers consider to be unfavorable for the participants to participate in the study or may affect adherence to the protocol. 6. Uncontrolled infection requiring intravenous administration of antibiotics, Antiviral drug or antifungal drugs.
Conditions Major Depressive Disorder
Phase NA
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary purpose of this study is to compare the short (12 week) and long-term (1-year) efficacy and the tolerability between stepwise psychopharmacotherapy and antidepressant monotherapy for 12 weeks in adult patients with major depressive disorders, stratified by the multimodal serum biomarker scores.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: stepwise pharmacotherapy — In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.
  • Drug: antidepressant monotherapy group — In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.

Primary Outcomes

  • Remission and treatment response status by Hamilton Depression Rating Scale (From baseline to 12 week, 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-08-03
Completion: 2030-12-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chonnam National University Hospital
Principal Investigators:
  • Jae-Min Kim, MD, PhD (PRINCIPAL_INVESTIGATOR) - Chonnam National University Hospital
Contact Information
Study Contact:
Jae-Min Kim, MD, PhD
82-62-220-6043
jmkim@chonnam.ac.kr
Hee-Ju Kang, MD, PhD
82-62-220-5961
hjkang82@chonnam.ac.kr
Young-Gwang Lee, CRC
82-62-220-6152
gloryworld@nate.com
Chonnam National University Hospital
Interventions
  • Drug: stepwise pharmacotherapy — In the stepwise pharmacotherapy group, treatment strategies (augmentation with antipsychotics (aripiprazole), augmentation with mood stabilizer (lithium),combination (mirtazapine)) will be determined every 3 weeks.
  • Drug: antidepressant monotherapy group — In the antidepressant monotherapy group, dosage escalation will be determined every 3 weeks.
Study Locations (1 sites)
Chonnam National University Hospital, Gwangju, 61469 South Korea
Eligibility Criteria
Inclusion Criteria: * 19 to 65 years * Diagnostic and Statistical Manual of Mental Disorders-IV criteria for major depressive disorder by study psychiatrists * Score≥17 on Hamilton Depression Rating Scale-17 * With ability to understand the objective of the study and sign informed consent * Initiation of an antidepressant treatment for the current episode or no psychotropics excluding sleep pills or benzodiazepines within 1 month of participation Exclusion Criteria: * Current or lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder not otherwise specified, or other psychotic disorders * current major depressive disorder with psychotic features * History of organic psychosis, epilepsy, or seizure disorder * Current anorexia nervosa or obsessive compulsive disorder * Unstable or uncontrolled medical condition * Unable to complete the psychiatric assessment or comply with the medication regimen due to a severe physical illness * History of anticonvulsant treatment * Electroconvulsive therapy for the current depressive episode * Hospitalization for any psychiatric diagnosis except depressive disorder (e.g., alcohol/drug dependence) * severly high risk of suicide, self-harm or homicide by investigator's assessment * Pregnant or breastfeeding * lack of treatment information on the current depressive episode
Conditions Preeclampsia
Phase PHASE3
Enrollment 294
Locations 17 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Preterm preeclampsia is a severe condition for both the mother and the fetus. Currently, the only treatment available to stop disease progression is termination/delivery of the fetus and placenta. Therefore, preterm preeclampsia carries the highest rates of neonatal morbidity and mortality due to iatrogenic preterm birth. There is evidence suggesting metformin, a drug commonly used to treat diabetes in and outside pregnancy, may be able to counter the pathophysiology of preeclampsia, raising the possibility that it could be used to treat the condition. This multi centre double blind randomised controlled trial aims to investigate if metformin can prolong gestation, lower neonatal length of stay and increase birthweight in a Nordic setting.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Metformin ER — Metformin ER, one gram three times daily taken orally. Once the participants have been recruited, they will start by taking one 500 mg tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
  • Drug: Placebo — Placebo, two tablets three times daily taken orally. Once the participants have been recruited, they will start by taking one tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.

Primary Outcomes

  • Pregnancy prolongation (From randomisation to delivery, measured in days and hours, up to 105 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-01-19
Completion: 2029-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 294 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Lina Bergman
Collaborators: The Swedish Research Council
Principal Investigators:
  • Lina Bergman, Associate professor (PRINCIPAL_INVESTIGATOR) - Sahlgrenska University Hospital
Contact Information
Study Contact:
Lina Bergman, Associate Professor
0046-3134307
lina.bergman@obgyn.gu.se
Pia Gudmundsson, PhD
0046-313434327
pia.gudmundsson@obgyn.gu.se
Pia Villa, Associate Professor
00358-405389779
pia.villa@helsinki.fi
Helsinki University Hospital
Interventions
  • Drug: Metformin ER — Metformin ER, one gram three times daily taken orally. Once the participants have been recruited, they will start by taking one 500 mg tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
  • Drug: Placebo — Placebo, two tablets three times daily taken orally. Once the participants have been recruited, they will start by taking one tablet three times a day. If well tolerated it will be increased day two to a maximum of two tablets three times a day. Treatment will continue until delivery. If there are side effects that are not tolerable, the dose will be decreased and the participant will remain blinded. Each participant will keep a treatment diary and number of tablets taken will be documented by the participant or hospital staff. The study will not alter or interfere with treatment or care routinely given for preterm preeclampsia.
Study Locations (17 sites)
Helsinki University Hospital, Helsinki, 00290 Finland
Tampere University Hospital, Tampere, 33520 Finland
Akershus University Hospital, Lørenskog, N-1474 Norway
Oslo University Hospital, Oslo, 0372 Norway
Södra Älvsborgs Hospital, Borås, 50455 Sweden
Falu Lasarett, Falun, 79129 Sweden
Sahlgrenska University Hospital, Gothenburg, 416 85 Sweden
Linköping University Hospital, Linköping, 581 85 Sweden
Skåne University Hospital, Lund, 221 85 Sweden
Skåne University Hospital, Malmö, 205 02 Sweden
Eligibility Criteria
Inclusion Criteria: * A diagnosis of preeclampsia (defined as hypertension in combination with significant proteinuria (albumin/creatinine ratio \>8 mg/mmol, protein/creatinine ratio\>30 mg/mmol or \>2+ protein on a urinary dipstick) has been made by the attending clinician * The managing clinicians have made the assessment to proceed with expectant management. * The subject has given written consent to participate in the study. * The woman must be 18 years of age or older * The gestational age is between 22+0 weeks to 33+6 weeks with a viable fetus * The woman carries a singleton pregnancy Exclusion Criteria: * Contraindications to treatment with metformin as outlined in SmPC * Contraindications for expectant management of preeclampsia such as an immediate indication for delivery according to SFOG guidelines for preeclampsia (https://www.sfog.se/media/338533/pe-riktlinje-230214.pdf). * Type 1 Diabetes Mellitus * Current use of metformin * Known or suspected allergies against metformin * Reluctance or language difficulties that result in difficulty understanding the meaning of study participation * Unable to understand the informed consent process * Previous participation in the study * Established fetal compromise that necessitates imminent delivery (including planned delivery after 48 hours of corticosteroid treatment). This will be decided by the clinical team before expectant management is offered to the patient. * Suspicion of a major known fetal anomaly or malformation. * Renal disease or dysfunction, suggested by a creatinine level greater than or equal to 125 µmol/L or rapidly declining renal function * Known acute or chronic metabolic acidosis, including diabetic ketoacidosis * Not suitable for inclusion by the opinion of the investigator
Conditions Depression, Anxiety
Phase NA
Enrollment 240
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal is to optimize peer coaching in order to optimize engagement and outcomes in digital therapy. The unmet mental health needs of community college students are staggering and a growing body of research demonstrates that therapy provided digitally with the assistance of trained community members without advanced degrees in mental health is an effective and scalable way to address these needs. Despite being effective for improving symptoms and functioning in those who engage in it, uptake and engagement in digital therapy is generally quite low. Recent research suggests that this is especially true of Latinx individuals, who tend to have unique and significant unmet mental health needs. To address these issues, Project 2 will examine treatment engagement, treatment satisfaction, symptoms and functioning outcomes among Latinx students at East Los Angeles College (ELAC) receiving digital therapy with peer coaching in the STAND program.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Demographic Matching — At randomization, students will be randomized to a Latinx or non-Latinx coach and will be informed whether or not their coach identifies as Latinx. Although we are not recruiting coaches or matching coaches with participants based on gender, gender identity or lived experience with mental health problems, we will collect these data from coaches in order to do conduct secondary exploratory analyses examining these variables as predictors or moderators of outcome.
  • Behavioral: Supervision Intensity — Coaches will be assigned to either standard supervision or reduced supervision, with equal distribution across Latinx vs non-Latinx. Coaches assigned to standard supervision will receive weekly supervision by a licensed provider consistent with the procedures outlined in the Data and Safety Monitoring Plan for the Signature Project. Coaches assigned to reduced supervision will attend weekly group supervision, but their session recordings or live sessions will not be reviewed by licensed supervisors or advanced peers and they will not receive personalized feedback about how they are performing in their sessions. Students will not be informed which supervision condition they have been assigned to in order to maintain high treatment expectancies. Of note, this design prohibits the coach and supervisors from being blind to participant condition.

Primary Outcomes

  • Engagement (Up to 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-26
Completion: 2026-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Los Angeles
Principal Investigators:
  • Amy Sewart, Ph.D. (PRINCIPAL_INVESTIGATOR) - University of California, Los Angeles
  • Kate Taylor, Ph.D. (PRINCIPAL_INVESTIGATOR) - University of California, Los Angeles
Contact Information
Study Contact:
Amelia Welborn, Ph.D.
916-202-5952
awelborn@mednet.ucla.edu
Tamar Kodish, Ph.D.
tamarkodish@ucla.edu
Areli Vargas
VARGASA3@ELAC.EDU
East Los Angeles College
Interventions
  • Behavioral: Demographic Matching — At randomization, students will be randomized to a Latinx or non-Latinx coach and will be informed whether or not their coach identifies as Latinx. Although we are not recruiting coaches or matching coaches with participants based on gender, gender identity or lived experience with mental health problems, we will collect these data from coaches in order to do conduct secondary exploratory analyses examining these variables as predictors or moderators of outcome.
  • Behavioral: Supervision Intensity — Coaches will be assigned to either standard supervision or reduced supervision, with equal distribution across Latinx vs non-Latinx. Coaches assigned to standard supervision will receive weekly supervision by a licensed provider consistent with the procedures outlined in the Data and Safety Monitoring Plan for the Signature Project. Coaches assigned to reduced supervision will attend weekly group supervision, but their session recordings or live sessions will not be reviewed by licensed supervisors or advanced peers and they will not receive personalized feedback about how they are performing in their sessions. Students will not be informed which supervision condition they have been assigned to in order to maintain high treatment expectancies. Of note, this design prohibits the coach and supervisors from being blind to participant condition.
Study Locations (1 sites)
East Los Angeles College, Los Angeles, California 91754 United States
Eligibility Criteria
Inclusion Criteria: * Currently enrolled in the East Los Angeles College * Either uninsured or covered by California Medicaid * Own or have private access to internet to complete the assessments and online prevention and therapy programs * Self-identify as Latinx. Exclusion Criteria: * Unable to fully comprehend the consent form, respond adequately to screening questions, or maintain focus or to sit still during assessment * Diagnosed with disorders requiring more specialized care (e.g., psychotic disorder, severe eating disorder, severe substance use disorder, severe neurological disorder), or marked cognitive impairment * Currently treated by psychiatrist or psychologist during timeframe that the treatment is offered through STAND and is unwilling to fully transfer care to STAND
Conditions HR+/HER2- Advanced Breast Cancer, Target...
Phase PHASE2
Enrollment 102
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To explore the efficacy and safety of chidamide combined with endocrine in phosphoinositide-3-kinase,catalytic,alpha gene(PI3KCA) wild type hormone receptor positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients and to explore the efficacy and safety of Everolimus combined with endocrine therapy in patients with PI3KCA Mutant HR+/HER2- advanced breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Everolimus — Everolimus combined with endocrine therapy(tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator)
  • Drug: Chidamide — Chidamide combined with endocrine therapy(tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator)
  • Drug: Endocrine therapy — Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.
  • Drug: Ovarian function suppression(OFS) — Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator.

Primary Outcomes

  • First stage progression free survival (PFS1) (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-07-20
Completion: 2027-07-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 102 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Fei Ma
010-87788120
drmafei@126.com
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Interventions
  • Drug: Everolimus — Everolimus combined with endocrine therapy(tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator)
  • Drug: Chidamide — Chidamide combined with endocrine therapy(tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator)
  • Drug: Endocrine therapy — Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.
  • Drug: Ovarian function suppression(OFS) — Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator.
Study Locations (1 sites)
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria: * The age at the time of signing the informed consent form is ≥ 18 years old and ≤ 75 years old, for menopausal/premenopausal women (premenopausal women need to receive ovarian function suppression treatment at the same time). * Breast cancer patients with HR positive (ER expression ≥ 10%, PR positive or negative) and HER2 negative (Immunohistochemical(IHC)0,1+; 2+, Fluorescence in situ hybridization(FISH) not expanded) confirmed by histology. * Histologically confirmed locally advanced breast cancer (no radical local treatment) or recurrent and metastatic breast cancer. * The patients who had previously progressed after the treatment of first-line or second-line cyclin-dependent kinases 4 and 6 inhibitors(CDK4/6 inhibitors)of endocrine and whose chemotherapy was ≤ second-line (relapse during the period of new adjuvant/adjuvant treatment or within 12 months after the end of treatment was regarded as first-line chemotherapy), the PIK3CA gene mutation detection was performed a. PIK3CA Mutant subjects were enrolled in queue A; b. PIK3CA wild-type subjects were included in queue B. * At least one measurable primary lesion (according to RECIST v1.1 standard) before enrollment. * The Eastern Oncology Collaborative Group (ECOG) physical fitness score is 0-2. * The toxic and side effects caused by previous anti-tumor therapy were relieved to 0-1 levels before the screening period (judged according to The NCI Common Terminology Criteria for Adverse Events version5.0 (NCICTCAE5.0); except for toxicity that researchers believe does not pose a safety risk to the subjects due to hair loss). * The functional level of organs must meet the following requirements: 1) Blood routine: Absolute neutrophil count(ANC)≥1.5 × 109/L (growth factor not used within 14 days); Platelet(PLT) ≥100 × 109/L (no corrective treatment used within 7 days); Hb ≥ 100 g/L (without corrective treatment within 7 days); 2) Blood biochemistry: Total bilirubin(TBIL) ≤1.5 × upper limits of normal(ULN); Glutamine aminotransferase(ALT),Glutamic transaminase(AST)≤3 × ULN; Glutamine transpeptidase(GGT) ≤2.5 × ULN; If there is liver metastasis, then ALT and/or AST ≤ 5 × ULN; Glutamine transpeptidase GGT ≤5 × ULN; Urea, Blood urea nitrogen (BUN), creatinine (Cr) ≤1.5 × ULN; 3) Cardiac ultrasound: Left ventricular ejection fraction(LVEF)≥ 50%; 4) 12 lead ECG: QT interval (QTcF) corrected by Fridericia method, male\<450ms, female. * Expected survival time ≥ 3 months. * Voluntarily participate in this clinical trial and sign a written informed consent form. Exclusion Criteria: * Those who have received any mammalian target of rapamycin(mTOR) and histone deacetylase(HDAC) inhibitors at any time in the past. * Received chemotherapy, Targeted therapy, immunotherapy, interventional therapy or other systematic anti-tumor treatment within 4 weeks before the first administration of the study drug, or received radiotherapy within 3 weeks Note: Nitroso urea or Mitomycin C is within 6 weeks before the first use of the study drug, oral fluorouracil and small molecule targeted drugs are within 2 weeks before the first use of the study drug or within 5 half lives of the drug (whichever is longer), Traditional Chinese medicine with anti-tumor indications should be used within 2 weeks before the first use of the study drug. * Subjects who have undergone major surgical procedures or obvious trauma within 4 weeks prior to enrollment, or are expected to undergo major surgical treatment. * Subjects with brain or subdural metastasis are excluded. Unless its stability has been maintained for at least 4 weeks or Asymptomatic brain metastasis can be included in the group. * According to the investigator's judgment, there are concomitant diseases (such as severe hypertension, Thyroid disease, hyperlipidemia, active infection, etc.) that seriously endanger the patient's safety or affect the patient's completion of the study. * Patients with poor control of diabetes shall be determined by the researcher. * Clinically obvious gastrointestinal abnormalities that may affect drug intake, transport or absorption (such as inability to swallow, chronic diarrhea, Bowel obstruction, etc.). * Severe cardiovascular injury (greater than a history of congestive heart failure at New York Heart Association(NYHA) level II, unstable angina or myocardial infarction within the past 6 months, or severe arrhythmia. * Subjects have active hepatitis (hepatitis B reference: HBsAg positive and hepatitis B virus(HBV) DNA ≥ 500 international unit(IU)/ml; hepatitis C reference: hepatitis C virus(HCV) antibody positive and HCV copy number\>upper limit of normal value); Subjects who are known to be positive for human immunodeficiency virus (HIV). * Female patients during pregnancy and lactation, female patients with Fertility and positive baseline Pregnancy test, or those of childbearing age who are unwilling to take effective contraceptive measures during the whole test period and within 90 days after the last administration of the study drug. * Have a clear history of neurological or mental disorders, including epilepsy or dementia, in the past. * Any medical condition in which the researcher believes that the subject is not suitable for entry into the study.
Conditions Pulmonary Hypertension, Chronic Obstruct...
Phase PHASE3
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

ERASE PH-COPD is a randomized double-blind study, with 2 parallel groups. Patients with severe pulmonary hypertension due to chronic obstructive pulmonary disease, will be randomly assigned to receive Tadalafil orally or placebo.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Tadalafil — Oral Tadalafil
  • Drug: Placebo — Oral Placebo

Primary Outcomes

  • 6 minute Walk (16 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-02-01
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Contact Information
Study Contact:
David Pr MONTANI, PU-PH
01 45 21 78 85
david.montani@aphp.fr
David Pr MONTANI
Kremlin Bicêtre
Interventions
  • Drug: Tadalafil — Oral Tadalafil
  • Drug: Placebo — Oral Placebo
Study Locations (1 sites)
Kremlin Bicêtre, Le Kremlin-Bicêtre, France 94270 France
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 and \<85 years at inclusion, * Dyspnea WHO functional class II to IV, * Severe precapillary pulmonary hypertension defined by : * a mean pulmonary artery pressure (mPAP) \>20 * associated with normal pulmonary artery wedge pressure (PawP ≤15 mmHg) * and pulmonary vascular resistance (PVR) \>5 WU * COPD diagnosed according to current international recommendation with persistent airflow limitation defined by post-bronchodilatator Forced expiratory volume in 1 second (FEV1) / forced vital capacity (FVC): FEV1/FVC \< 0.70, * Naive patients from PDE5i (sildenafil, tadalafil) PH treatments and who did not receive other specific PH treatment in the last 3 months (bosentan, ambrisentan, macitentan, riociguat, epoprostenol, treprostinil, iloprost), * Treatments for COPD need to be stable for at least 1 month before screening visit, * Patients who fulfill criteria for a supplemental long-term oxygen therapy need to be supplied sufficiently before study entry. The amount of supplemental oxygen and the delivery method need to be stable for at least 1 month before screening visit, * Patients who are able to understand and follow instructions and who are able to participate in the study for the entire period, * Patients must have given their written informed consent to participate in the study after having received adequate previous information and prior to any study-specific procedures, * Affiliation to a social security regime, Exclusion Criteria: * Patients with a medical disorder, condition, or history of such that would impair the patient's ability to participate or complete this study in the opinion of the investigator, * Patients with underlying medical disorders and anticipated life expectancy below 12 months (eg active cancer disease with localized and/or metastasized tumor mass), * PH not due to chronic respiratory diseases (group 1, 2, 4 or 5 of the clinical classification of PH), * Other respiratory diseases: interstitial lung disease, sarcoidosis, lymphangioleiomyomatosis, histiocytosis, or untreated severe sleep apnea disorders, * 6-minutes walk distance \< 50 m or patients unable to perform the 6-minutes walk test, * Exacerbation of the COPD requiring hospitalization in the last 8 weeks before screening, * COPD with mild (\> 80% predicted value) or severe (FEV1 \<30% predicted value) airflow limitation, * Patients listed for lung transplantation at the time of inclusion, * Systolic left ventricular dysfunction with left ventricular ejection fraction \<40% on echocardiography, * Patient on AME (state medical aid), * Participation in another clinical trial during the preceding 3 months and during the study, * Pregnant women, or breast-feeding women, or women with childbearing potential not using a combination of condoms and a safe and highly effective contraception method (hormonal contraception with implants or oral contraceptives, or intrauterine devices) and one month after the end of the study, WOCBP include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal \[defined as amenorrhea ≥ 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level \> 35 mIU/mL\], * Patient under guardianship or curatorship Non-inclusion criteria related to treatment by tadalafil: * Contraindication to tadalafil: * Severe renal failure (creatinine clearance \< 30 mL/min/1,73 m2) * Severe liver cirrhosis Child-Plugh C * Severe systemic hypotension \<90/50 * Recent myocardial infarction \<90 days * Medical history of anterior ischemic optic neuropathy * Hypersensitivity to tadalafil or any of the excipients * Concomitant use of potent CYP3A4 inhibitors or inducers, soluble guanylate cyclase stimulator (riociguat), other PDE5 inhibitors or nitrates or doxazosin * Cardiovascular diseases: * Clinically significant aortic and mitral valve disease * Pericardial constriction * Restrictive or congestive cardiomyopathy * Significant left ventricular dysfunction * Life-threatening arrhythmias * Symptomatic coronary artery disease * Uncontrolled hypertension. * Angulation of the penis, cavernosal fibrosis, Peyronie's disease or history of priapism * Pulmonary or upper respiratory infection requiring antibiotics, or pulmonary embolism in the last 4 weeks before screening * Participation in a respiratory rehabilitation program within the 4 weeks prior to screening or scheduled during the study period * Right heart failure necessitating catecholamine support within the 4 weeks prior to screening.
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase PHASE3
Enrollment 2400
Locations 963 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Drug: Carboplatin — Given IV
  • Drug: Cyclophosphamide — Given IV
  • Drug: Docetaxel — Given IV
  • Drug: Doxorubicin — Given IV
  • Drug: Paclitaxel — Given IV
  • Biological: Pembrolizumab — Given IV
  • Other: Quality-of-Life Assessment — Ancillary studies

Primary Outcomes

  • Breast cancer event-free survival (BC-EFS) (Up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-09-15
Completion: 2033-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Priyanka Sharma (PRINCIPAL_INVESTIGATOR) - SWOG Cancer Research Network
Contact Information
Study Contact:
Alicia Aranda
210-614-8808
aaranda@swog.org
Dana Sparks
210-614-8808
dsparks@swog.org
Site Public Contact
205-895-1816
charlesbaldwin@uabmc.edu
University of Alabama at Birmingham Cancer Center
Interventions
  • Procedure: Biospecimen Collection — Undergo collection of blood samples
  • Drug: Carboplatin — Given IV
  • Drug: Cyclophosphamide — Given IV
  • Drug: Docetaxel — Given IV
  • Drug: Doxorubicin — Given IV
Study Locations (963 sites)
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama 35233 United States
Anchorage Associates in Radiation Medicine, Anchorage, Alaska 98508 United States
Anchorage Radiation Therapy Center, Anchorage, Alaska 99504 United States
Alaska Breast Care and Surgery LLC, Anchorage, Alaska 99508 United States
Alaska Oncology and Hematology LLC, Anchorage, Alaska 99508 United States
Alaska Women's Cancer Care, Anchorage, Alaska 99508 United States
Anchorage Oncology Centre, Anchorage, Alaska 99508 United States
Katmai Oncology Group, Anchorage, Alaska 99508 United States
Providence Alaska Medical Center, Anchorage, Alaska 99508 United States
Fairbanks Memorial Hospital, Fairbanks, Alaska 99701 United States
Eligibility Criteria
Inclusion Criteria: * Participants must have histologically confirmed estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative breast cancer (TNBC) defined as ER \< 5%, PR \< 5%, and HER2 negative (per 2020 American Society of Clinical Oncology \[ASCO\] College of American Pathologists \[CAP\] guidelines) * NOTE: Participants with weakly ER or PR positive disease, defined as ER and/or PR between 1-4% by immunohistochemistry, are eligible if adjuvant endocrine therapy is not recommended/planned by the treating physician * Participants must have American Joint Committee on Cancer (AJCC) 8 anatomic tumor clinical stage either * T2-T4, N0, M0 or * T1-T3, N1-2, M0 * Note: All participants with clinically suspicious nodes must undergo core needle biopsy or fine needle biopsy per standard clinical practice to pathologically confirm nodal status * Participants must have breast and axillary imaging with mammogram and/or ultrasound and/or magnetic resonance imaging (MRI) within 49 days prior to randomization * Note: Participants with bilateral invasive breast cancer are eligible if both breast cancers are ER-negative, PR-negative, and HER2-negative provided they meet the other eligibility criteria * Participants must not have T4/N+, any N3, or inflammatory breast cancer * Participants must not have metastatic disease (M1) * Participants must not have received prior systemic therapy or radiation therapy with curative intent for the current breast cancer * Participants must not have had previous definitive ipsilateral breast surgery for the current breast cancer * Participants must not have current or anticipated use of other investigational agents while participating in this study * Participants must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition as study agents * Participants must not have severe hypersensitivity (\>= grade 3) to pembrolizumab or any of its excipients * Participants must not have received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, CD137) * Participants must not be currently participating in or have participated in a study of an investigational agent or used an investigational device within 28 days prior to randomization * Participants must be \>= 18 years old * Participants must have Zubrod performance status of 0-2 * Participants with evidence of peripheral neuropathy must have it at =\< grade 1, by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 5.0, within 28 days prior to randomization * Participants must have a complete medical history and physical exam within 28 days prior to randomization * Hemoglobin \>= 9.0 g/dL or \>= 5.6 mol/L (within 28 days prior to randomization) * (Criteria must be met without erythropoietin dependency and without packed red blood cell transfusion within last 2 weeks) * Leukocytes \>= 3 x 10\^3/uL (within 28 days prior to randomization) * Absolute neutrophil count \>= 1.5 x 10\^3/uL (within 28 days prior to randomization) * Platelets \>= 100 x 10\^3/uL (within 28 days prior to randomization) * Total bilirubin =\< 1.5 x institutional upper limit of normal (IULN), OR direct bilirubin =\< IULN for participants with total bilirubin \> 1.5 x IULN (unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =\< 5 x institutional IULN) (within 28 days prior to randomization) * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 3 x institutional upper limit of normal (ULN) (within 28 days prior to randomization) * Participants must have a serum creatinine =\< the IULN OR calculated creatinine clearance \>= 50 mL/min/1.73m\^2 using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28 days prior to registration * Participants must have adequate cardiac function. Participants must have left ventricular ejection fraction \>= 50% as assessed by either echocardiography (ECHO) or multigated acquisition scan (MUGA) assessed within 28 days prior to registration. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification and must be class 2B or better * Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at randomization and have undetectable viral load test on the most recent test results obtained within 6 months prior to randomization * Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load while on suppressive therapy on the most recent test results obtained within 6 months prior to randomization, if indicated * Note: No testing for Hepatitis B is required unless mandated by local health authority * Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have undetectable HCV viral load test on the most recent test results obtained within 6 months prior to randomization, if indicated * Note: No testing for hepatitis C is required unless mandated by local health authority * Participants with history of diabetes must not have uncontrolled diabetes in the opinion of the treating investigator * Participants must not have uncontrolled hypertension in the opinion of the treating investigator * Participants must not have had a major surgery within 14 days prior to randomization. Participants must have fully recovered from the effects of prior major surgery in the opinion of the treating investigator * Participants must not have severe or active infections within 14 days prior to Randomization, including but not limited to hospitalization for infection, bacteremia, or severe pneumonia * Participants must not have a diagnosis of immunodeficiency and be receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization * Participants must not have active autoimmune disease that has required systemic treatment in 2 years prior to randomization (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment * Participants must not have a history of (non-infectious) pneumonitis that required steroids, or has current (non-infectious) pneumonitis * Participants must not have received a live vaccine within 30 days prior to randomization. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist \[registered trademark\]) are live attenuated vaccines and are not allowed * Participants must not have a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the treatment regimen * Participants must not be pregnant or nursing. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potentia